TMJ, postmarket, surveillance
Category Archives: Drug Safety Information Podcasts
FDA approves drug to reduce risk of preterm birth in at-risk pregnant women
The U.S. Food and Drug Administration today approved Makena (hydroxyprogesterone caproate) injection to reduce the risk of preterm delivery before 37 weeks of pregnancy, in pregnant women with a history of at least one spontaneous preterm birth.
FDA clears first diagnostic radiology application for mobile devices
iPhone, iPad, radiology
FDA reminds health care professionals about safe use of non-sterile alcohol prep pads
Following a recent recall of potentially contaminated non-sterile alcohol prep pads, the U.S. Food and Drug Administration today reminded health care professionals about the safe use of non-sterile alcohol prep pads to clean and disinfect the surface of the skin.
Fourth FDA orphan drug designation workshop scheduled for Feb. 28 – March 1, 2011
The U.S. Food and Drug Administration has scheduled its fourth orphan drug designation workshop for academics, biotechnology companies, and those unfamiliar with the process for Feb. 28 – March 1, 2011, in Claremont, Calif. in collaboration with Keck Graduate Institute.
FDA review indicates possible association between breast implants and a rare cancer
ALCL, breast implants
FDA approves Viibryd to treat major depressive disorder
Vlibryd, depressive disorder
Maine seafood processor enters into consent decree with FDA
The U.S. Food and Drug Administration announced today that the Portland Shellfish Co., Inc.; Jeffrey D. Holden, company president; Satyavan Singh, quality manager; and John A. Maloney, general manager, have signed a consent decree prohibiting them from distributing seafood in interstate commerce until the FDA has approved in writing the company’s Hazard Analysis and Critical Control Point (HACCP) plans, sanitation program and Listeria monocytogenes (L. mono) testing program. (DSK)
FDA Approves Head Lice Treatment for Children and Adults
The U.S. Food and Drug Administration today approved Natroba (spinosad) Topical Suspension 0.9% for the treatment of head lice infestation in patients ages 4 years and older.
FDA to improve most common review path for medical devices
510(k), device, innovation